Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00038298
Status:
COMPLETED
Last Update Posted:
2011-01-21
First Post:
2002-05-29
Brief Title:
A Rheumatoid Arthritis RA Study Treating Signs and Symptoms of RA in People With RA Receiving Methotrexate
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
A Multicenter Randomized Double-Blind Placebo-Controlled Dose Ranging Study to Assess the Efficacy Safety and Tolerability of AMG 719 in Subjects With Rheumatoid Arthritis Receiving Methothrexate
Status:
COMPLETED
Status Verified Date:
2011-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This clinical study is investigating AMG 719 an investigational drug for the treatment of patients who have Rheumatoid Arthritis and who are taking Methotrexate AMG 719 is a drug which is self-injected beneath the skin similarly to the way insulin is self-injected by diabetics Patients on this study are on study for 28-weeks They visit the study facility at least 11 times while participating in the study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None